Stock market guru SP Tulsian of sptulsian.com remains positive on two pharmaceutical stocks, Biocon and Divi's Laboratories.

“We have been taking a buy call on Aurobindo Pharma which we have stopped recommending for the last 3-4 months. We are now focusing on two stocks -- Biocon and Divi's Laboratories. If you really take a call on Aurobindo, then definitely it looks overstretched or maybe overreaction because if you take the valuation call probably the stock has come in the single digit PE multiple that looks quite attractive. But no point in just chasing the stock on the pure valuation basis when the sentiments are weak,” he noted.

Talking about Yes Bank he said: “Wait for the Q2 results; if you don’t see any shocking revelations on the asset quality, then things will start moving up from there. I see Rs 30-35 as a good support with Rs 50 in the near term or maybe in this month itself.”

According to Tulsian, the DGFT rejection of the claim of Container Corporation of India (CONCOR) is seen as negative but that is acting more as a trigger and allowing the share to settle at about Rs 550. "You will see the buying with vengeance coming back making the stock to move back to Rs 600. We will be buyer in the stock maybe at about Rs 550-555,” he observed.